Sarah Verhoeff

121 [89Zr]Zr-DFO-avelumab PET/CT in early stage NSCLC patients Correlating [89Zr]Zr-DFO-avelumab uptake with treatment response and PD-L1 expression The [89Zr]Zr-DFO-avelumab PET/CT TTB ratio (Spearman ρ -0.67, p = 0.01) and SUVpeak (Spearman ρ -0.59, p = 0.04) was correlated to pathological response (Figure 5). The PD-L1 expression as determined by IHC could be correlated to [89Zr]Zr-DFO-avelumab SUVpeak (Pearson r 0.86, p=0.014; Spearman ρ 0.62, p= 0.14). A B Figure 5. Scatterplot Figure 5A displays the correlation of [89Zr]Zr-DFO-avelumab TTB ratio and pathological response (n=13). Of note: 2 lesions with the same TTB ratio. Figure 5B displays the correlation of [89Zr]Zr-DFO-avelumab SUVpeak (B) of all lesions imaged with the optimal tracer dose and available pathological response rate (n=13). 6